CTLA4-Ig: a novel immunosuppressive agent

Bibliography

• SUTHANTHIRAN M, STROM TB: Renal transplantation. N Engl. J. Med. (1994) 331(6): 365–376.
   PubMed Web of Science ®Google Scholar
• BRAZELTON TR, MORRIS RE: Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rap amycin), mycophe-nolate mofetil and leflunomide. CUIT. Opin. Immunol (1996) 8(5):710–720.
   PubMed Web of Science ®Google Scholar
• NORMAN DJ: Mechanisms of action and overview of OK'D. Ther. Drug Monit. (1995) 17 (6) :615–620.
   PubMed Web of Science ®Google Scholar
• SCHREIBER SL, CRABTREE GR: The mechanism of action of cyclosporin A and FK506. Immunol. Today (1992) 13(4):136–142.
   PubMedGoogle Scholar
• CHUNG J, KUO CJ, CRABTREE GR, BLENIS J: Rap amycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 Kd S6 protein kinases. Cell (1992) 69(7):1227–1236.
   PubMed Web of Science ®Google Scholar
• SUZUKI H, KUNDIG TM, FURLONGER C et al.: Deregu-lated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science (1995) 268(5216):1472–1476.
   PubMed Web of Science ®Google Scholar
• SADLACK B, LOHLER J, SCHORLE H et al.: Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and prolifera-tion of CD4+ T cells. Eur. J. Immunol. (1995) 25 (11):3053–3059.
   PubMed Web of Science ®Google Scholar
• DAI Z, LAKKIS FG: The role of cytokines, CTLA-4 and costimulation in transplant tolerance and rejection. Curr. Opin. Immunol. (1999) 1 1 (5): 504–508.
   Google Scholar
• NAGANO H, TILNEY NL: Chronic allograft failure: the clinical problem. Am]. Med. Sci. (1997) 313 (5):305–309.
   PubMed Web of Science ®Google Scholar
• REISER H, STADECKER MJ: Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl. J. Med. (1996) 335(18):1369–1377.
   PubMed Web of Science ®Google Scholar
• SAYEGH MH, TURKA LA: The role of T-cell costimula-tory activation pathways in transplant rejection. N Engl. J. Med. (1998) 3 38 (25):1813–1821.
   Google Scholar
• LINSLEY PS, LEDBETTER JA: The role of the CD28 receptor during T cell responses to antigen. Ann. Rev. Immunol. (1993) 11:191–212.
   PubMed Web of Science ®Google Scholar
• JUNE CH, BLUESTONE JA, NADLER LM, THOMPSON CB: The B7 and CD28 receptor families. Immunol. Today (1994) 15(7):321–331.
   PubMedGoogle Scholar
• LINSLEY PS, BRADY W, URNES M, GROSMAIRE LS, DAMLE NK, LEDBETTER JA: CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. (1991) 174 (3):561–569.
   PubMed Web of Science ®Google Scholar
• WALUNAS TL, BAKKER CY, BLUESTONE JA: CTLA-4 ligation blocks CD28-dependent T cell activation [published erratum appears in J Exp Med 1996 Jul 1;184(1):301]. J. Exp. Med. (1996) 1 83 (6):2541–2550.
   Google Scholar
• TIVOL EA, BORRIELLO F, SCHWEITZER AN, LYNCH WP, BLUESTONE JA, SHARPE AH: loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgantissue destruction, revealing a critical negative regulatory role of CTIA-4. Immunity (1995) 3(5):541–547.
   PubMed Web of Science ®Google Scholar
• GUINAN EC, GRIBBEN JG, BOUSSIOTIS VA, FREEMAN GJ, NADLER LM: Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood (1994) 84(10):3261–3282.
   PubMed Web of Science ®Google Scholar
• WALUNAS TL, LENSCHOW DJ, BAKKER CY et al.: CTIA-4 can function as a negative regulator of Tcell activation. Immunity (1994) 1 (5):405–413.
   PubMed Web of Science ®Google Scholar
• VAN PARIJS L, ABBAS AK: Homeostasis and self-tolerance in the immune system: turning lympho-cytes off. Science (1998) 280(5360:243–248.
   PubMedGoogle Scholar
• TIVOL EA, BOYD SD, MCKEON S et al: CTIA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice. J. Immunol. (1997) 158(10:5091–5094.
   PubMedGoogle Scholar
• PEREZ VL, VAN PARIJS L, BIUCKIANS A, ZHENG XX, STROM TB, ABBAS AK: Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity (1997) 6(4):411–417.
   PubMed Web of Science ®Google Scholar
• JUDGE TA, WU Z, ZHENG XG, SHARPE AH, SAYEGH MH, TURKA LA: The role of CD80, CD86 and CTIA4 in alloimmune responses and the induction oflong-term allograft survival. J Immunol. (1999) 162 (4):1947–1951.
   PubMed Web of Science ®Google Scholar
• LINSLEY PS, GREENE JL, BRADY W, BAJORATH J, LEDBETTER JA, PEACH R: Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTIA-4 receptors [published erratum appears in Immunity 1995 Feb;2(2):following 203]. Immunity (1994) 1 (9):793–801.
   PubMed Web of Science ®Google Scholar
• GIMMI CD, FREEMAN GJ, GRIBBEN JG, GRAY G, NADLER LM: Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc. Natl. Acad. Sci. USA (1993) 9 0 (14):6586–6590.
   Google Scholar
• SCHWARTZ RH: T cell clonal anergy. Curr. Opin. Immunol. (1997) 9(3):351–357.
   PubMedGoogle Scholar
• NOEL PJ, BOISE LH, GREEN JM, THOMPSON CB: CD28 costimulation prevents cell death during primary T cell activation. J Immunol. (1996) 157 (2):636–642.
   PubMed Web of Science ®Google Scholar
• LINSLEY PS, WALLACE PM, JOHNSON J et al.: Irnmuno-suppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science (1992) 257 (5071):792–795.
   PubMed Web of Science ®Google Scholar
• KHOURY SJ, AKALIN E, CHANDRAKER A et al: CD28-B7 costimulatory blockade by CTIA4Ig prevents actively induced experimental autoimmune encephalomye-litis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J. Immunol. (1995) 155 (10):4521–4524.
   PubMed Web of Science ®Google Scholar
• SAYEGH MH, AKALIN E, HANCOCK WW et al: CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp. Med. (1995) 181 (5):1869–1874.
   PubMed Web of Science ®Google Scholar
• KEARNEY ER, WALUNAS TL, KARR RW et al.: Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. J. Immunol (1995) 155 (3):1032–1036.
   PubMed Web of Science ®Google Scholar
• KUCHROO VK, DAS MP, BROWN JA et al: B7-1 and B7-2costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Ce//(1995) 80(5)707–718.
   Google Scholar
• LENSCHOW DJ, WALUNAS TL, BLUESTONE JA: CD28/B7system of T cell costimulation. Ann. Rev. Immunol (1996) 14:233–258.
   PubMed Web of Science ®Google Scholar
• PEACH RJ, BAJORATH J, BRADY W et al.: Complemen-tarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1. J. Exp. Med. (1994) 180 (6):2049–2058.
   PubMed Web of Science ®Google Scholar
• HARRIS N, PEACH R, NAEMURA J, LINSLEY PS, LE GROS G,RONCHESE F: CD80 costimulation is essential for the induction of airway eosinophilia. J Exp. Med. (1997) 185(0:177–182.
   PubMedGoogle Scholar
• TAN P, ANASETTI C, HANSEN JA et al.: Induction ofalloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7 /BB1. J. Exp. Med. (1 9 9 3) 177(0:165–173.
   Google Scholar
• LENSCHOW DJ, ZENG Y, THISTLETHWAITE JR et al.:Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA41g. Science (1992) 257 (5071):789–792.
   PubMed Web of Science ®Google Scholar
• CABRIAN KM, BERRY KK, SHUFORD WW, MITTLER RS, RODGERS JN, LINSLEY PS: Suppression of T-cell-dependent immune responses in monkeys by CTIA4Ig. Transplant. Proc. (1996) 28 (6) :3261–3262.
   PubMed Web of Science ®Google Scholar
• SRINIVAS NR, WEINER RS, SHYU WC et al.: Apharmacoki-netic study of intravenous CTIA4Ig, a novel immuno-suppressive agent, in mice. J. Pharm. Sci. (1996) 85 (3):296–298.
   PubMed Web of Science ®Google Scholar
• SRINIVAS NR, SHYU WC, WEINER RS, TAY LK, GREENE DS,BARBHAIYA RH: Ph armacokinetics of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following intravenous and subcutaneous administra-tion to mice. J Pharm. Sci. (1995) 84(12):1488–1489.
   PubMed Web of Science ®Google Scholar
• ABRAMS JR, LEBWOHL MG, GUZZO CA et al.: CTIA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J. Clin. Invest. (1999) 103 (9) :1243–1252.
   PubMed Web of Science ®Google Scholar
• FINCK BK, LINSLEY PS, WOFSY D: Treatment of murinelupus with CTIA4Ig. Science (1994) 265 (5176):1225–1227.
   PubMed Web of Science ®Google Scholar
• WEBB LM, WALMSLEY MJ, FELDMANN M: Prevention andamelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Eur. J. Immunol (1996) 26(10):2320–2328.
   PubMed Web of Science ®Google Scholar
• REYNOLDS J, TAM FW, CHANDRAKER A et al.: CD28-B7blockade prevents the development of experimental autoimmune glomerulonephritis. j Clin. Invest. (2000) 105 (5):643–651.
   PubMed Web of Science ®Google Scholar
• NISHIKAWA K, LINSLEY PS, COLLINS AB, STAMENKOVIC I, MCCLUSKEY RT, ANDRES G: Effect of CTLA-4 chimeric protein on rat autoimmune anti-glomerular basement membrane glomerulonephritis. Eur. J. Immunol. (1994) 2 4 (6):1249–1254.
   Google Scholar
• LENSCHOW DJ, HO SC, SATTAR H et al: Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med. (1995) 181 (3):1145–1155.
   PubMed Web of Science ®Google Scholar
• SCHAUB M, ISSAZADEH S, STADLBAUER TH, PEACH R, SAYEGH MH, KHOURY SJ: Costimulatory signal blockade in murine relapsing experimental autoim-mune encephalomyelitis. J. Neuroimmunol (1999) 96 (2):158–166.
   PubMed Web of Science ®Google Scholar
• TANG A, JUDGE TA, NICKOLOFF BJ, TURKA LA: Suppres-sion of murine allergic contact dermatitis by CTLA4-Ig. Tolerance induction of Th2 responses requires additional blockade of CD40-ligand. j /mmundi (1996) 157(0:117–125.
   Google Scholar
• DJUKANOVIC R: The role of co-stimulation in airway inflammation. Clin. Exp. Allergy (2000) 3 0 (Suppl. 1):46–50.
   Google Scholar
• KEANE-MYERS A, GAUSE WC, LINSLEY PS, CHEN SJ, WILLS-KARP M: B7 -CD28 /CTLA-4 co stimulato ry pathways are required for the development of Thelper cell 2-mediated allergic airway responses to inhaled antigens. J. Immunol (1997) 158(5):2042–2049.
   PubMed Web of Science ®Google Scholar
• KRINZMAN SJ, DE SANCTIS GT, CERNADAS M et al: Inhibition of T cell costimulation abrogates airway hyperresponsiveness in a murine model. j an. Invest. (1996) 98(12):2693–2699.
   PubMed Web of Science ®Google Scholar
• TAKADA M, CHANDRAKER A, NADEAU KC, SAYEGH MH, TILNEY NL: The role of the B7 costimulatory pathway in experimental cold ischemia/reperfusion injury. J Clin. Invest. (1997) 1 00 (5) :1199–1203.
   Google Scholar
• QIAN J, COLLINS M, SHARPE AH, HOYER LW: Prevention and treatment of Factor VIII inhibitors in murine hemophilia A. Blood (2000) 95(4):1324–1329.
   PubMed Web of Science ®Google Scholar
• ISRAEL-ASSAYAG E, FOURNIER M, CORMIER Y: Blockade of T cell costimulation by CTLA4-Ig inhibits lung inflammation in murine hypersensitivity pneumo-nitis. j Immunol (1999) 163 (12):6794–6799.
   PubMed Web of Science ®Google Scholar
• VIA CS, RUS V, NGUYEN P, LINSLEY P, GAUSE WC: Differ-ential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD. J. /mmuno/. (1996) 157 (9):4258–4267.
   PubMed Web of Science ®Google Scholar
• BLAZAR BR, TAYLOR PA, LINSLEY PS, VALLERA DA: In vivo blockade of CD28/CTLA4: B7 /BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood (1994) 83 (12):3815–3825.
   PubMed Web of Science ®Google Scholar
• BLAZAR BR, TAYLOR PA, PANOSKALTSIS-MORTARI A, GRAY GS, VALLERA DA: Coblockade of the LFAl:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts. Blood (1995) 85 (9):2607–2618.
   PubMed Web of Science ®Google Scholar
• HAKIM FT, CEPEDA R, GRAY GS, JUNE CH, ABE R: Acute graft-versus-host reaction can be aborted by blockade of co stimulatory molecules. J. thimuno/. (1995) 155 (4) :1757–1766.
   PubMed Web of Science ®Google Scholar
• TURKA LA, LINSLEY PS, LIN H et al.: T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc. Nati Acad. Sci. USA (1992) 89 (22):11102–11105.
   PubMed Web of Science ®Google Scholar
• LIN H, BOLLING SF, LINSLEY PS et al.: Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp. Med. (1993) 1 7 8 (5):1801–1806.
   Google Scholar
• PEARSON TC, ALEXANDER DZ, HENDRIX R et al.: CTLA4-Ig plus bone marrow induces long-term allograft survival and donor specific unresponsive-ness in the murine model. Evidence for hematopoietic chimerism. Transplantation (1996) 61 (7):997–1004.
   Google Scholar
• SAYEGH MH, ZHENG XG, MAGEE C, HANCOCK WW, TURKA LA: Donor antigen is necessary for the preven-tion of chronic rejection in CTLA4Ig-treated murine cardiac allograft recipients. Transplantation (1997) 64 (12) :1646–1650.
   PubMed Web of Science ®Google Scholar
• PERICO N, IMBERTI O, BONTEMPELLI M, REMUZZI G: Toward novel antirejection strategies: in vivo immunosuppressive properties of CTLA4Ig. Kidney/nt. (1995) 47 (1):241–246.
   PubMed Web of Science ®Google Scholar
• BOLLING SF, LIN H, TURKA LA: The time course of CTLAIg effect on cardiac allograft rejection. j Surg. Res. (1996) 63(0:320–323.
   PubMedGoogle Scholar
• PERICO N, AMUCHASTEGUI S, BONTEMPELLI M, REMUZZI G: CTLA4Ig alone or in combination with low-dose cyclosporine fails to reverse acute rejection of renal allograft in the rat. Transplantation (1996) 61 (9):1320–1322.
   PubMed Web of Science ®Google Scholar
• RUSSELL ME, HANCOCK WW, AKALIN E et al.: Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. J. an. Invest. (1996) 97 (3):833–838.
   Google Scholar
• AZUMA H, CHANDRAKER A, NADEAU K et al.: Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection [see comments]. Proc. Natl. Acad. Sci. USA (19 9 6) 93 (22):12439–12444.
   Google Scholar
• CHANDRAKER A, AZUMA H, NADEAU K et al.: late blockade of T cell costimulation interrupts progres-sion of experimental chronic allograft rejection. J Clin. Invest. (1998) 101 (10:2309–2318.
   PubMedGoogle Scholar
• CHANDRAKER A, RUSSELL ME, GLYSING-JENSEN T, WILLETT TA, SAYEGH MH: T-cell co stimulatory blockade in experimental chronic cardiac allograft rejection: effects of cyclosporine and donor antigen. Transplantation (1997) 63 (8):1053–1058. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (2000) 9(9)
   Google Scholar
• BOLLING SF, UN H, WET RQ, LINSLEY P, TURKA LA: The effect of combination cyclosporine and CTLA4-Ig therapy on cardiac allograft survival. j. Surg. Res. (1994) 57 (1):60–64.
   PubMed Web of Science ®Google Scholar
• WOODWARD JE, QIN L, CHAVIN KD et al: Blockade of multiple costimulatory receptors induces hypore-sp onsiveness: inhibition of CD2 plus CD28 pathways. Transplantation (1996) 62(7):1011–1018.
   PubMed Web of Science ®Google Scholar
• LI Y, ZHENG XX, LI XC, ZAND MS, STROM TB: Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Transplantation (1998) 66 (10) :1387–1388.
   PubMed Web of Science ®Google Scholar
• YIN D, FATHMAN CG: Induction of tolerance to heart allografts in high responder rats by combining an ti-CD4 with CTLA4Ig. J. Immunol. (1 9 9 5) 155 (01655–1659.
   Google Scholar
• GRASER E, RISCH K, LINSLEY PS et al.: Synergism of CTLA4-IG and anti-CD4 monoclonal antibody treatment in a rat kidney transplant model. Transplant. Proc. (1997) 29(1-2):1307–1309.
   PubMed Web of Science ®Google Scholar
• HALE DA, GOTTSCHALK R, MAKI T, MONACO AP: Use of CTLA4-Ig in combination with conventional immuno-suppressive agents to prolong allograft survival. Transplantation (1997) 64 (6):897–900.
   PubMed Web of Science ®Google Scholar
• LARSEN CP, ELWOOD ET, ALEXANDER DZ et al.: Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature (1996) 381 (6580:434–438.
   PubMedGoogle Scholar
• MARK W, HECHENLEITNER P, SAYEGH MH, HANCOCKWW, CANDINAS D: Importance of the CD28 /B7 costimulatory pathway in the development of chronic ductopenic rejection in a new model of orthotopic rat liver allo transplantation. Transplant. Proc. (1997) 29 (1-2):1029.
   PubMed Web of Science ®Google Scholar
• TU Y, REHMAN A, FLYE MW: CTLA4-Ig treatment prolongs rat or thotopic liver graft survival. Transplant. Proc. (1997) 29(1-2):1036–1037.
   PubMed Web of Science ®Google Scholar
• JORDAN SC, MATSUMARA Y, ZUO XJ, MARCHEVSKY A, LINSLEY P, MATLOFF J: Donor-specific transfusions enhance the immunosuppressive effects of single-dose cyclosporine A and CTLA4-Ig but do not result in long-term graft acceptance in a histoincompatible model of rat lung allograft rejection. Transpl. Immunol (1996) 4(0:33–37.
   PubMedGoogle Scholar
• YIN DP, SANKARY HN, WILLIAMS J, KRIEGER N, FATHMAN CG: Induction of tolerance to small bowel allografts in high-responder rats by combining an ti-CD4 with CTLA4Ig. Transplantation (1996) 62(10:1537–1539.
   PubMedGoogle Scholar
• KIRK AD, HARLAN DM, ARMSTRONG NN et al.: CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl. Acad. Sci. USA (1997) 94 (16):8789–8794.
   PubMed Web of Science ®Google Scholar
• LEVISETTI MG, PADRID PA, SZOT GL et al.:Inimuno sup-pressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J Immunol. (1997) 159(10:5187–5191.
   PubMedGoogle Scholar
• GUINAN EC, BOUSSIOTIS VA, NEUBERG D et al.: Transplantation of anergic histoincompatible bone marrow allografts. N. Engl. J. Med. (1999) 340(22):1704–1714.
   PubMed Web of Science ®Google Scholar